Summary of Clinical Data
Latest study demonstrated effective oral delivery with an EMISPHERE® carrier in a 10-day multiple dose safety study
Consistent with previous Phase I results, the maximum Cromolyn plasma concentrations were achieved in less than 30 minutes; concentration amounts absorbed were significantly higher than those seen with pulmonary delivery of Cromolyn at therapeutic doses
Continuing to progress with additional Phase I studies
Well tolerated; no adverse events reported